ClinicalTrials.gov
public full text
Public Domain
In Vivo Noradrenergic System and Aging
The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson's disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs (\[11C\]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)#872259
- Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline#1085545
- A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.#918970
- Neurostimulation for Sleep Disordered Breathing#1140624
- Multivariate age-related variations in quantitative MRI maps: Widespread age-related differences revisited#132287
Record · ID 1370932
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive